New insight into clinical development of nucleic acid aptamers.

摘要: Nucleic acid-based aptamers have been shown as high-affinity ligands and potential antagonists of disease-associated proteins. Aptamers, isolated from combinatorial libraries by an iterative in vitro selection process, discriminate between closely related targets are characterized high specificity low toxicity thus representing a valid alternative to antibodies target specific proteins biomedical interest. Moreover, they non-immunogenic can be easily stabilized chemical modifications expanding their therapeutic potential. Here, we will focus on the structural functional features that entered clinical development pipeline together with those holding great therapeutics preclinical studies. The future perspectives discussed well.